---
title: "Hierarchical Bayesian Modeling of Antibody Kinetics: Extensions and Refinements"
author: "Kwan Ho Lee"
institute: "UC Davis"
date: today
format: 
  html: default
  beamer:
    theme: Madrid
    slide-level: 2
    keep-tex: true
    toc: false
    incremental: false
engine: knitr
bibliography: references.bib
env:
  PAK_CACHE_DISABLE: "true"
---

## Overview

-   Incorporates feedback from Dr. Morrison, Dr. Aiemjoy, and lab discussion
-   Focus exclusively on [@teunis2016] two-phase within-host model
-   Clarifies full hierarchical Bayesian modeling structure
-   Explicitly distinguishes between priors, hyperpriors, transformations
-   Reorders: **Start from observation model → build upward**

------------------------------------------------------------------------

## Big Picture: What Are We Modeling?

We are modeling **how antibody levels change over time** in response to infection, using multiple individuals and multiple biomarkers (antigen-isotype combinations, (j = 1, 2, $\dots$, 10)).

Goals:

-   Understand the **average pattern** for each biomarker
-   Allow for **individual-level variation**
-   **Share information** across individuals to improve inference

This motivates using a **hierarchical Bayesian model**.

------------------------------------------------------------------------

## Step 1: Observation Model (Data Level)

Observed (log-transformed) antibody levels:

$$
\log(y_{\text{obs},ij}) \sim \mathcal{N}(\log(y_{\text{pred},ij}(\theta_{ij})), \tau_j^{-1})
$$ {#eq-1}

Measurement precision prior:

$$
\tau_j \sim \text{Gamma}(a_j, b_j)
$$ {#eq-2}

------------------------------------------------------------------------

## Parameter Summary

| Symbol   | Description                             |
|----------|-----------------------------------------|
| $\mu_y$  | Antibody production rate (growth phase) |
| $\mu_b$  | Pathogen replication rate               |
| $\gamma$ | Clearance rate (by antibodies)          |
| $\alpha$ | Antibody decay rate                     |
| $\rho$   | Shape of antibody decay (power-law)     |
| $t_1$    | Time of peak response                   |
| $y_1$    | Peak antibody concentration             |

: Parameter summary for antibody kinetics model. {#tbl-param-summary}

**Note:** Only the first 6 are typically estimated. $y_1$ is derived from the ODE solution at $t_1$.

------------------------------------------------------------------------

## Step 2: Within-Host ODE System [@teunis2016]

$$
\frac{dy}{dt} = 
\begin{cases}
\mu_y y(t), & t \leq t_1 \\
- \alpha y(t)^\rho, & t > t_1
\end{cases}
\quad \text{and} \quad
\frac{db}{dt} = \mu_b b(t) - \gamma y(t)
$$ {#eq-3}

-   Initial conditions: $y(0) = y_0$, $b(0) = b_0$
-   Transition at $t_1$: when $b(t_1) = 0$

------------------------------------------------------------------------

## Step 3: Closed-Form Solutions

**Antibody concentration:**

-   For $t \leq t_1$: $$
    y(t) = y_0 e^{\mu_y t}
    $$ {#eq-4}
-   For $t \> t_1$: $$
    y(t) = y_1 \left(1 + (\rho-1)\alpha y_1^{\rho-1}(t-t_1)\right)^{-\frac{1}{\rho-1}}
    $$ {#eq-5}

**Pathogen load:**

-   For $t \leq t_1$: $$
    b(t) = b_0 e^{\mu_b t} - \frac{\gamma y_0}{\mu_y - \mu_b} \left( e^{\mu_y t} - e^{\mu_b t} \right)
    $$ {#eq-6}
-   For $t \> t_1$: $$
    b(t) = 0
    $$

------------------------------------------------------------------------

## Step 4: Derived Quantities

-   **Clearance Time** $t_1$:

    $$
    t_1 = \frac{1}{\mu_y - \mu_b} \log\left(1 + \frac{(\mu_y - \mu_b) b_0}{\gamma y_0}\right)
    $$ {#eq-7}

-   **Peak Antibody Level** $y_1$:

    $$
    y_1 = y_0 e^{\mu_y t_1}
    $$ {#eq-8}

**Important**: $t_1$ and $y_1$ are **derived**, not fit parameters.

------------------------------------------------------------------------

## Full Parameter Model (7 Parameters)

**Subject-level parameters** for each subject$i$ and biomarker $j$:

$$
\theta_{ij} \sim \mathcal{N}(\mu_j,\, \Sigma_j), \quad \theta_{ij} =
\begin{bmatrix}
y_{0,ij} \\
b_{0,ij} \\
\mu_{b,ij} \\
\mu_{y,ij} \\
\gamma_{ij} \\
\alpha_{ij} \\
\rho_{ij}
\end{bmatrix}
$$ {#eq-9}

-   These 7 parameters represent the **full biological model** (antibody + pathogen dynamics)

------------------------------------------------------------------------

## From Full 7 Parameters to 5 Latent Parameters

-   Although the model estimates 7 parameters, for modeling antibody kinetics $y(t)$, we focus on **5-parameter subset**:

$$y_0,\ \ t_1 (\text{derived}),\ \  y_1 (\text{derived}),\ \  \alpha,\ \  \rho$$

-   These 5 parameters are **log-transformed** into the latent parameters $\theta\_{ij}$ used for modeling.

------------------------------------------------------------------------

## Core Parameters Used for Curve Drawing

Although the full model estimates **7 parameters**, only **5 key parameters** required to draw antibody curves:

-   $y_0$: initial antibody level
-   $t_1$: time of peak antibody response (derived)
-   $y_1$: peak antibody level (derived)
-   $\alpha$: decay rate
-   $\rho$: shape of decay

Note: $t_1$ and $y_1$ are **derived from the full model** - These 5 are sufficient for prediction and plotting

------------------------------------------------------------------------

## Step 5: Subject-Level Parameters (Latent Version)

Each subject $i$ and biomarker $j$ has latent parameters:

$$
\theta_{ij} =
\begin{bmatrix}
\log(y_{0,ij}) \\
\log(y_{1,ij} - y_{0,ij}) \\
\log(t_{1,ij}) \\
\log(\alpha_{ij}) \\
\log(\rho_{ij} - 1)
\end{bmatrix}
$$ {#eq-10}

Distribution:

$$
\theta_{ij} \sim \mathcal{N}(\mu_j, \Sigma_j)
$$

------------------------------------------------------------------------

## Step 6: Parameter Transformations (log scale priors)

JAGS implements latent parameters (par) as:

| Model Parameter | Transformation in JAGS     |
|:----------------|:---------------------------|
| $y_0$           | $\exp(\text{par}_1)$       |
| $y_1$           | $y_0 + \exp(\text{par}_2)$ |
| $t_1$           | $\exp(\text{par}_3)$       |
| $\alpha$        | $\exp(\text{par}_4)$       |
| $\rho$          | $\exp(\text{par}_5) + 1$   |

: Log-Scale Transformations of Antibody Model Parameters in JAGS. {#tbl-transformation}

All priors are thus applied on **log scale** (or log-minus-one for $\rho$).

------------------------------------------------------------------------

## Step 7: Population-Level Parameters (Priors)

The biomarker-specific mean vector $\mu_j$ has a **hyperprior** :

$$
\mu_j \sim \mathcal{N}(\mu_{\text{hyp},j}, \Omega_{\text{hyp},j})
$$ {#eq-11}

Where:

-   $\mu_{\text{hyp},j}$ : **prior mean** for the population-level parameters\
-   $\Omega_{\text{hyp},j}$ : **prior covariance** encoding uncertainty about $\mu_j$ (e.g., $100 \cdot I_7$ for weakly informative prior)

**Clarification:**

-   $\mu_{\text{hyp},j}$ defines the **center of a distribution, not** a single point guess.

-   In Bayesian modeling, **priors and hyperpriors are distributions** over unknown quantities, capturing full uncertainty.

------------------------------------------------------------------------

## Step 8: Prior on Covariance Matrices

We also don’t know how much individual parameters vary. So we assign a **Wishart prior** to the **inverse** covariance matrix:

$$
\Sigma_j^{-1} \sim \mathcal{W}(\Omega_j, \nu_j)
$$ {#eq-12}

-   $\Omega_j$ : prior scale matrix (small variance across parameters, often $0.1 \cdot I_7$)
-   $\nu_j$ : degrees of freedom

Higer $\nu_j$ $\rightarrow$ more inofrmative prior (stronger prior).

Lower $\nu_j$ $\rightarrow$ more weakly informative (broader prior or weaker prior).

This tells the model how much we expect individuals to vary from the average for biomarker $j$.

------------------------------------------------------------------------

## Putting It All Together

The model is built hierarchically across five conceptual levels:

1.  **Observed data:** noisy log antibody concentrations from serum samples
2.  **Latent individual parameters:** hidden antibody dynamics $\theta_{ij}$ for each subject-biomarker pair
3.  **Population-level means:** average antibody parameters for each biomarker
4.  **Hyperpriors on means:** our belief about the likely range of biomarker-specific population means
5.  **Priors on variability:** our belief about how much individual parameters vary around the population mean

This structure allows us to account for uncertainty at every level, while borrowing strength across subjects and biomarkers.

------------------------------------------------------------------------

## Summary of the Hierarchy

1.  **Top Level**:

    -   For each biomarker $j$, the true mean antibody trajectory parameters $\mu_j$ come from a prior:
        -   $\mu_j \sim \mathcal{N}(\mu_{\text{hyp},j}, \Omega_{\text{hyp},j})$

2.  **Middle Level**:

    -   For each person $i$, their parameters:
        -   $\theta_{ij} \sim \mathcal{N}(\mu_j, \Sigma_j)$

3.  **Bottom Level**:

    -   Their actual observed antibody levels are noisy measurements of predictions from $\theta_{ij}$:
        -   $\log(y_{\text{obs},ij}) \sim \mathcal{N}(\log(y_{\text{pred},ij}(\theta_{ij})), \tau_j^{-1})$

Where:

-   $y_{\text{pred},ij}(\theta_{ij})$ is the predicted antibody trajectory based on $\theta{ij}$.
-   So predictions directly use $\theta_{ij}$ to compute $y_{\text{pred},ij}$, and then compare to observed data.

------------------------------------------------------------------------

## Clarification: How Bottom Level Depends on Middle Level

We know the following facts:

1.  $\theta_{ij}$ are the **subject-level latent parameters** (like $y_0, b_0, \mu\_b, \mu\_y, \gamma, \alpha, \rho$).
2.  From $\theta_{ij}$, we **calculate** the antibody trajectory $y_{\text{pred},ij}(t)$ using the ODE solution.
3.  The **observed log-antibody** $\log(y_{\text{obs},ij})$ is modeled as a **noisy version** of $\log(y_{\text{pred},ij})$.
4.  $\tau_j$ is the precision (measurement noise precision for biomarker $j$).

Thus, at the **Bottom Level**, we model:

$$
\log(y_{\text{obs},ij}) \sim \mathcal{N}(\log(y_{\text{pred},ij}(\theta_{ij})), \tau_j^{-1})
$$

Here:

-   The **mean** is $\log(y_{\text{pred},ij}(\theta_{ij}))$ — depends on the **ODE solution** which itself depends on $\theta_{ij}$.
-   The **variance** is $\tau_j^{-1}$ — shared across individuals for a given biomarker.

Summary:

-   Meaning: Observations depend indirectly on latent parameters $\theta_{ij}$ via predictions $y_{\text{pred}}$.

------------------------------------------------------------------------

## Model Comparison [@teunis2016] vs. Our Presentation

| Component           | [@teunis2016]         | This Presentation          |
|:--------------------|:----------------------|:---------------------------|
| Pathogen ODE        | $\mu_0 b(t) - c y(t)$ | $\mu_b b(t) - \gamma y(t)$ |
| Antibody growth ODE | $\mu y(t)$            | $\mu_y y(t)$               |
| Antibody decay ODE  | $-\alpha y(t)^r$      | $-\alpha y(t)^\rho$        |
| Growth mechanism    | Pathogen-driven       | Self-driven                |

: Comparison of Teunis (2016) model and this presentation’s model assumptions. {#tbl-model-comparison}
